We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Switching to Arimidex Reduces Relapse Rate in Breast Cancer Patients, Study Shows
Switching to Arimidex Reduces Relapse Rate in Breast Cancer Patients, Study Shows
November 20, 2006
A new breast cancer study shows that switching to AstraZeneca's Arimidex after several years of treatment with tamoxifen increases survival and reduces the chances of relapse by about half in postmenopausal women.